Helmholtz-Zentrum für Infektionsforschung GmbH

TOKYO, May 8, 2024 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximately JPY 1.64 billion (USD 10.8 million1) in four projects for the development of new drugs for malaria and neglected tropical diseases (NTDs).2 The GHIT Fund invests in the development of new drugs, vaccines, and diagnostics for neglected infectious diseases such as malaria, tuberculosis, and NTDs, which predominantly affect the world's vulnerable and underserved populations. These R&D projects must involve partnerships between Japanese and non-Japanese organizations, and the four new projects consist of diverse partnerships including Japanese pharmaceutical companies and universities, as well as non-Japanese research institutions and universities. The GHIT Fund will invest approximately JPY 444 million (USD 2.9 million1) in two malaria projects: the development of malaria chemoprevention drug through a partnership among Shionogi & Co., Ltd., Nagasaki University, National Institute of Infectious Diseases, and Medicines for Malaria Venture (MMV), and therapeutic drug development led by Eisai Co., Ltd., the Scripps Research Institute, and International Centre for Genetic Engineering and Biotechnology (ICGEB). For NTDs, the GHIT Fund will also invest approximately JPY 1.2 billion (USD 7.9 million1) in two projects: drug development for onchocerciasis and lymphatic filariasis led by Eisai Co., Ltd., University Hospital Bonn, and Helmholtz Centre for Infection Research, and the development of a treatment for Chagas disease led by Mitsubishi Tanabe Pharma Corporation and Drugs for Neglected Diseases initiative (DNDi). The GHIT Fund plays a catalytic role in matching Japanese and global partners to accelerate R&D resulting in the support of over 180 development partners since 2013. Through global partnerships, the GHIT Fund aims to promote open innovation in R&D and create an environment that enables the rapid delivery of products to patients in need. Please refer to Appendix 1 for a detailed description of each project and its development stage. As of March 31, 2024, the GHIT Fund invested in 36 projects, including 12 discovery projects, 16 preclinical projects, and 8 clinical trials3 in the portfolio. The total amount of investments since 2013 is JPY 33.2 billion (USD 219 million) (Appendix 2). 1 USD1 = JPY151.33, the approximate exchange rate on March 31, 2024. 2 These awarded projects were selected and approved as new investments from among proposals to RFP2023-001 for the Product Development Platform, which was open for applications from November 2022 to July 2023. 3 This number includes projects in the registration phase. The GHIT Fund is a Japan-based international public-private partnership (PPP) fund that was formed between the Government of Japan, multiple pharmaceutical companies, the Bill & Melinda Gates Foundation, Wellcome, and the United Nations Development Programme (UNDP). The GHIT Fund invests in and manages an R&D portfolio of development partnerships aimed at addressing neglected diseases, such as malaria, tuberculosis, and neglected tropical diseases, which afflict the world's vulnerable and underserved populations. In collaboration with global partners, the GHIT Fund mobilizes Japanese industry, academia, and research institutes to create new drugs, vaccines, and diagnostics for malaria, tuberculosis, and neglected tropical disease s. Appendix 1. Project Details G2023-218 G2023-108 G2023-211 G2023-209 *All amounts are listed at an exchange rate of USD1 = JPY151.33, the approximate exchange rate on March 31, 2024. Appendix 2. Investment Overview (as of March 31, 2024) Investments to date Total investments: 33.2 billion yen (USD 219 million1) Total invested projects: 125 (36 active projects and 89 completed projects) To learn more about GHIT Fund's investments, please visit Investment Overview: Portfolio: Advancing Portfolio: Clinical Candidates: For more information, contact: Nancy Moss, 254-729-991-028, [email protected] Mina Ohata at +81-36441-2032 or [email protected] SOURCE Global Health Innovative Technology Fund (GHIT Fund)

Researchers have identified how the tick-borne Crimean-Congo haemorrhagic fever virus enters our cells. The results are an important step in the development of drugs against the deadly disease. Researchers at Karolinska Institutet, in collaboration with JLP Health and others, have identified how the tick-borne Crimean-Congo haemorrhagic fever virus enters our cells. The results are published in Nature Microbiology and are an important step in the development of drugs against the deadly disease. Crimean-Congo haemorrhagic fever virus (CCHF virus) is spread through tick bites and can cause haemorrhagic fever. The disease is serious and has a mortality rate of up to 40 per cent depending on the health status of the person infected. Common symptoms include fever, muscle pain, abdominal pain, joint pain, vomiting and haemorrhaging that can cause organ failure. The disease has spread to Europe The virus is present in around 40 countries, including Central Asia, the Middle East and parts of Africa. In recent years, the disease has spread to new geographical areas as a result of climate change, including Spain and France. The tick species that can spread the disease has also been observed in Germany and Sweden. There are currently no effective treatments for the disease. In a new study, researchers at Karolinska Institutet in Sweden and others have found that the virus enters our cells via a protein on the cell surface, the so-called LDL receptors that regulate blood cholesterol levels. To identify the protein, the researchers used human mini-organs grown in test tubes and an advanced stem cell library from JLP Health. The same platform has previously been used to identify how the Ebola virus enters cells. The results were also confirmed in tests on mice, which showed that mice lacking the LDL receptor did not get as sick as others. Researchers want to trick the virus The discovery is an important step towards developing drugs for Crimean-Congo haemorrhagic fever, according to Ali Mirazimi, adjunct professor at the Department of Laboratory Medicine, Karolinska Institutet, and one of the researchers behind the study. "Once we know which receptor the virus uses, we can produce the receptor in test tubes and administer it as a drug," he says. "Then we can trick the virus into binding to those receptors instead of to the cells and thus stop the virus from spreading in our bodies." This knowledge is essential if the disease were to become more common and spread to new areas. Normally it takes many years to develop a drug, but the COVID-19 pandemic and the development of the SARS-CoV-2 vaccine showed that it can be done much faster if everyone decides it is a priority. Ticks are spread by migratory birds "This is an important step in our preparedness for the disease," says Ali Mirazimi. "Crimean-Congo haemorrhagic fever is a disease we would rather not have. The ticks are spread by migratory birds and have already been found in Sweden. If the disease starts appearing in more places, we may already have a drug that we can take into clinical trials." The research was conducted in collaboration with the Medical University of Vienna, Austria, Helmholtz Centre for Infection Research, Germany, the National Institutes of Health, USA, and the company JLP Health. It was financed mainly by the Swedish Research Council and the EU. No conflicts of interest have been reported.

DUBLIN--( BUSINESS WIRE )--The "Acquired Gene or Chromosome Alterations Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2023 Update" report has been added to ResearchAndMarkets.com's offering. Acquired Gene or Chromosome Alterations Pipeline Report provides comprehensive information about the Acquired Gene or Chromosome Alterations pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress. This report offers extensive coverage of Acquired Gene or Chromosome Alterations under development, providing comprehensive insights into pipeline products, major players, developmental activities, clinical trial data, and recent developments in the segment/industry. Acquired Gene or Chromosome Alterations comprises of reagents employed for genetic testing to detect cancer causing/ related alterations, such as; k-ras, BRCA 1+2, Telomerase and HER-2/neu (human epidermal growth factor receptor 2). The report reviews the details of major pipeline products, including product descriptions, licensing and collaboration details, and other developmental activities related to Acquired Gene or Chromosome Alterations. It also lists all the pipeline projects involving major players engaged in the development of Acquired Gene or Chromosome Alterations. Coverage of pipeline products is based on various stages of development, ranging from Early Development to Approved/Issued stages, allowing readers to understand the progress of these products in the pipeline. Key clinical trial data related to ongoing trials specific to pipeline products in the Acquired Gene or Chromosome Alterations segment is provided, offering valuable insights into the clinical development of these products. Reasons to Buy Formulate significant competitor information, analysis, and insights to improve R&D strategies Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage Identify and understand important and diverse types of Acquired Gene or Chromosome Alterations under development Develop market-entry and market expansion strategies Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline In-depth analysis of the product's current stage of development, territory and estimated launch date Key Topics Covered: 1 Table of Contents 1.1 List of Tables 1.2 List of Figures 2 Introduction 2.1 Acquired Gene or Chromosome Alterations Overview 3 Products under Development 3.1 Acquired Gene or Chromosome Alterations - Pipeline Products by Stage of Development 3.2 Acquired Gene or Chromosome Alterations - Pipeline Products by Territory 3.3 Acquired Gene or Chromosome Alterations - Pipeline Products by Regulatory Path 3.4 Acquired Gene or Chromosome Alterations - Pipeline Products by Estimated Approval Date 3.5 Acquired Gene or Chromosome Alterations - Ongoing Clinical Trials 4 Acquired Gene or Chromosome Alterations - Pipeline Products under Development by Companies 4.1 Acquired Gene or Chromosome Alterations Companies - Pipeline Products by Stage of Development 4.2 Acquired Gene or Chromosome Alterations - Pipeline Products by Stage of Development 5 Acquired Gene or Chromosome Alterations Companies and Product Overview 6 Acquired Gene or Chromosome Alterations- Recent Developments 7 Appendix A selection of companies mentioned in this report includes Abital Pharma Pipelines Ltd Admera Health LLC Agena Bioscience Inc Aix-Marseille University Albert Ludwigs University of Freiburg Apteryx Imaging Inc Baruch S. Blumberg Institute Baylor College of Medicine bioMerieux SA Biotype Innovation GmbH Blondin Bioscience, LLC Cardiff Oncology Inc Cepheid Inc Children's Hospital Los Angeles Children's Hospital of Philadelphia China Medical Technologies Inc (Inactive) Chronix Biomedical Inc Columbia University Duke University Empire Genomics LLC Fred Hutchinson Cancer Research Center French National Institute of Health and Medical Research Garvan Institute of Medical Research Gencurix Inc Genetag Technology, Inc Genomic Health Inc GenomicTree Co Ltd German Cancer Research Center H. Lee Moffitt Cancer Center & Research Institute Inc Heali Ltd Hebrew University of Jerusalem Heidelberg Pharma AG Helmholtz Centre for Infection Research Inform Genomics Inc Institute of Cancer Research Interpace Biosciences Inc iTP Biomedica Corp Johns Hopkins University Massachusetts General Hospital Mayo Clinic McGill University MDNA Life Sciences Inc MolecularMD Corp Myriad International GmbH Nel ASA Northern California Institute for Research and Education NucleoBio Inc Ohio State University OmicsWay Corp Oxford Biodynamics Plc Oxford Cancer Biomarkers Ltd Pennsylvania State University Princess Margaret Cancer Centre QuantuMDx Group Ltd Queen's University Belfast Rosetta Genomics Ltd (Inactive) Stanford University Stony Brook University Syamala Srinivasa Life Sciences Pvt. Ltd Telo Genomics Corp The Chinese University of Hong Kong The University of New South Wales press Limited The Walter and Eliza Hall Institute of Medical Research TheraDiag SA Therawis Diagnostics GmbH Thrive Earlier Detection Corp Total Brain Ltd Trinity College Dublin University College London University of California San Diego University of Cambridge University of Central Florida University of Cologne University of Copenhagen University of Hawaii at Manoa University of Montreal University of Rochester University of South Carolina University of Southern California University of Strathclyde University of Sydney University of Texas Medical Branch at Galveston University of Washington Vyant Bio Inc Wistar Institute Yaathum Biotech Pvt Ltd Yale University For more information about this report visit https://www.researchandmarkets.com/r/fb39kc About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.